@Article{biocell.2022.018847,
AUTHOR = {ZHIYONG ZHANG, YAN PAN, YAN ZHAO, MUDAN REN, YARUI LI, YUN FENG, GUIFANG LU, SHUIXIANG HE},
TITLE = {Knockdown Wiskott-Aldrich syndrome protein family member 3 (WASF3) inhibits colorectal cancer metastasis and sensitizes to cisplatin through targeting ZNF471},
JOURNAL = {BIOCELL},
VOLUME = {46},
YEAR = {2022},
NUMBER = {8},
PAGES = {1917--1924},
URL = {http://www.techscience.com/biocell/v46n8/47573},
ISSN = {1667-5746},
ABSTRACT = {Colorectal cancer (CRC) is a heterogeneous cancer, and many risk factors for colorectal cancer have been
established. For CRC metastasis, tumor cell migration, adhesion as well as invasion are important processes. WiskottAldrich syndrome protein family member 3 (WASF3) is necessary for metastasis of various types of cancers. However,
its role in CRC progression has not been fully elucidated. This study examined the in vitro functional roles of WASF3 in
the CRC and explored the underlying molecular mechanisms. We used siRNA-WASF3 to gene silence WASF3 in colon
cancer cell (HCT116) in vitro. The effects of WASF3 silencing on HCT116 cell apoptosis, proliferation, migration, as
well as invasion were assessed by flow cytometry, CCK-8, and transwell assays. ZNF471 protein expressions were
detected by immunofluorescence staining and RT-PCR. Moreover, the effects of ZNF471 were studied on a series of in
vitro antitumor-promoting assays using HCT116. WASF3 knockdown expression using small interfering RNA (siRNA)
ameliorated CRC cell proliferation, anchorage-independent growth, invasion, and metastasis. Furthermore, we observed
that WASF3 contributed to upregulating the metastasis signaling pathway through inhibiting the expression of ZNF471.
Our study suggests that targeting WASF3 signaling might be a novel therapeutic strategy for treating CRC.},
DOI = {10.32604/biocell.2022.018847}
}